HMGB1 and neoplasm: Evodiamine, a novel anti-tumor drug, can inhibit proliferation and induce apoptosis of tumor cells; in an OSCC transplantation tumor rat model, it could target the binding of HMGB1 and RAGE, thus modulating the AGE/RAGE downstream signaling system, thereby inhibiting the proliferation, invasion, and angiogenesis in OSCC [44].